Patent · US Expired

Moncyclic L-nucleosides analogs

US6552183B1 · kind B1 · utility

54Cited by
17References
2Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 7, 2000
Grant dateApr 22, 2003
Priority date
Expiry dateJun 28, 2021

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P37/06
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.